drugset / Trial / NCT04311580

Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure

NCT04311580

NaSingle-groupOpen-labelTreatment

Summary

Patients with urothelial high risk non-muscle invasive bladder cancer patients will be treated with intravesical electromotive drug administration/mitomycin (EMDA/MMC) after bacillus Calmette-Guerin (BCG) failure. Patients are scheduled for an initial 6 weekly treatments, a further 6 weekly treatments for non-responders and a followup 10 monthly treatments for responders. Complete response will be defined as histological disappearance of malignancy on bladder biopsy and resolution of abnormal cytological findings after treatment. Time to first recurrence, time to progression, overall survival, and disease-specific survival wil be estimated by use of the Kaplan-Meier method.

Timeline

Start
2000-01-01
Primary completion
2013-12-31
Completion
2020-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitomycin C Other / unclassified 40 mg Intravenous